Sarah Cannon Research Institute
Sara King is a seasoned professional in the clinical research field, currently serving as a Strategic Partnership Executive and Clinical Project Lead at Sarah Cannon Research Institute since November 2014. Prior experience includes the role of Director of Site Development at Wake Research Associates from February to October 2014 and Director of Non-Oncology Operations at Sarah Cannon Research Institute from November 2005 to July 2012, where responsibilities encompassed fiscal management, study operations, and patient recruitment. Additionally, Sara King held the position of Advertising and Patient Recruitment Manager, focusing on maximizing clinical trial success through strategic relationships. Sara King holds a Bachelor of Science degree in Marketing and Finance from Virginia Commonwealth University - School of Business.
This person is not in any teams
Sarah Cannon Research Institute
Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. In 2022, SCRI formed a joint venture with former US Oncology Research to enhance clinical trial access and availability across the country. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted nearly 700 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. The combined research network brings together physicians who are actively accruing patients to clinical trials at more than 250 locations in 26 states across the US.